AI generated summary of Pubmed citation/abstract with PMID 38091824

https://pubmed.ncbi.nlm.nih.gov/38091824

Piplerlongumine-based nanomedicine shows promise in impairing the glycolytic metabolism of triple negative breast cancer stem cells, suggesting a potential new treatment approach.